Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

MiNK Therapeutics, Inc. (INKT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
13.56+1.12 (+9.00%)
At close: 4:00PM EDT
13.56 0.00 (0.00%)
After hours: 04:07PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.44
Open12.44
Bid11.36 x 1100
Ask14.81 x 2200
Day's Range12.13 - 13.68
52 Week Range11.20 - 13.68
Volume48,869
Avg. Volume203,775
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    MiNK Therapeutics Announces Closing of Initial Public Offering

    NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the closing of its previously announced initial public offering of 3,333,334 shares of its common stock at a public offering price of $12.00 per share. All of the shares were offered by

  • Barrons.com

    Paragon 28 Stock Gains in Trading Debut, While MiNK Rebounds

    The IPO market ended the week with two companies—medical-device maker Paragon 28 and biotech MiNK Therapeutics—listing their shares.

  • GlobeNewswire

    MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering

    NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (“MiNK”), a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the pricing of its initial public offering of 3,333,334 shares of common stock at a public offering price of $12.00 per share. The gross proceeds of the offering, before deduc

Advertisement
Advertisement